Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma
| Autor: | Mikio Okayama, Jun Kato, Kota Mizuno, Taku Kikuchi, Masatoshi Sakurai, Takahiro Kamiya, Takehiko Mori, Yuya Koda, Tomohiko Tanigawa |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Palliative care Adolescent Lymphoma Nausea medicine.drug_class Vomiting medicine.medical_treatment Severity of Illness Index Drug Administration Schedule Ondansetron Young Adult Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Antiemetic Humans Aged Retrospective Studies Cisplatin Aged 80 and over Chemotherapy business.industry Disease Management Hematology Middle Aged Regimen Treatment Outcome Antiemetics Female medicine.symptom business medicine.drug |
| Zdroj: | Hematology (Amsterdam, Netherlands). 26(1) |
| ISSN: | 1607-8454 |
| Popis: | This study aimed to evaluate the antiemetic efficacy of a 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA), ondansetron, in patients with malignant lymphoma receiving multi-day cisplatin-based combination chemotherapy.We conducted a single-institution retrospective analysis of patients receiving the first course of an ESHAP (etoposide, cisplatin, methylprednisolone, cytarabine) regimen including 4-day continuous infusion of cisplatin (25 mg/mEighty-two patients were analyzed. Nausea and vomiting were generally well controlled, with the CR rates of emesis being 79% in the overall phase, 82% in the early phase (days 1-6), and 89% in the delayed phase (days 7-10). TC and CP were achieved in 51 patients (62%) and 77 patients (94%) in the overall phase.Most of the chemotherapy regimens for lymphoid malignancies include high-dose corticosteroid which may be also effective as antiemetics. Although NK1 receptor antagonist (NK1RA) is generally recommended for cisplatin-containing chemotherapy, it can interact with variety drugs.Although NK1RA is generally recommended for cisplatin-containing regimen, our results suggest that ondansetron effectively controlled emesis in patients receiving ESHAP therapy which includes high-dose corticosteroid. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|